Liraglutide And Semaglutide Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Liraglutide And Semaglutide Market By 2029?

The liraglutide and semaglutide market size has seen rapid expansion in recent years. It is forecast to increase from $15.19 billion in 2024 to $16.94 billion in 2025, at a compound annual growth rate (CAGR) of 11.5%. This historical growth can be attributed to the rising prevalence of diabetes, the increasing incidence of diseases linked to obesity, an expansion in the number of clinical trials, growing investment in diabetes research and development, and an increasing demand for convenient treatment alternatives.

The liraglutide and semaglutide market size is anticipated to expand swiftly over the coming years. This market is projected to reach $26.07 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.4%. Several factors contribute to this projected increase, including the growing acceptance of GLP-1 receptor agonists, an uptick in healthcare spending, the broadening of pharmaceutical companies’ product ranges, increasing levels of disposable income, and a rising elderly population prone to diabetes. Key developments expected during this forecast timeframe encompass the incorporation of digital health platforms, the implementation of customized dosing approaches, continuous improvements in drug delivery methods, the creation of biosimilar alternatives, and the integration of artificial intelligence in guiding treatment decisions.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

Which Industry Drivers Are Expected To Accelerate The Liraglutide And Semaglutide Market From 2025 To 2029?

The increasing incidence of diabetes is projected to stimulate the expansion of the liraglutide and semaglutide markets moving ahead. This chronic ailment involves abnormally high blood glucose concentrations, stemming from the body’s resistance to insulin and inadequate insulin secretion. The growing population of individuals with diabetes can be attributed to inactive routines, unhealthy eating patterns, and genetic susceptibilities. Liraglutide and semaglutide play a crucial role in managing diabetes, providing effective control over blood glucose and mitigating the dangers of diabetes-related complications. As an illustration, in June 2024, the National Health Service, a government department in the UK, reported that in 2023, the NHS detected an additional 549,000 people in England at risk of developing type 2 diabetes. This raised the total number of individuals with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP, to 3,615,330. This marks a substantial increase from the 3,065,825 recorded in 2022, indicating an almost 20% surge. Consequently, the expanding population of diabetic individuals is a key driver for the liraglutide and semaglutide markets.

What Are The Segment Types Shaping The Liraglutide And Semaglutide Market?

The liraglutide and semaglutidemarket covered in this report is segmented –

1) By Type: Pills; Liquid

2) By Administration: Parenteral; Oral

3) By Application: Type 2 Diabetes Mellitus; Obesity; Other Applications

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Pills: Oral Tablets (Liraglutide, Semaglutide); Extended-Release Oral Formulations

2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide); Pre-Filled Syringes; Vials For Injection

Which Competitive Trends Are Defining The Liraglutide And Semaglutide Market Structure?

Leading firms within the liraglutide and semaglutide markets are creating anti-diabetic biosimilar medications, aiming to improve glucose regulation and lessen cardiovascular dangers for individuals with diabetes. These anti-diabetic biosimilars represent economical, nearly identical versions of existing diabetes biologics, designed to provide equivalent therapeutic advantages. As an illustration, in January 2024, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical firm, introduced a biosimilar variant of the widely used anti-diabetic medicine, Liraglutide, marking its inaugural release in India. This product is a biosimilar of Liraglutide, an anti-diabetic medication used to enhance glycemic control in adults diagnosed with type 2 diabetes mellitus. The introduction of this drug lowers daily treatment expenses, thereby considerably broadening access for a greater number of patients across the nation. With a price point of approximately INR 100 for a typical 1.2 mg daily dose, this product dramatically cuts therapy expenditures by about 70% and necessitates a prescription for acquisition.

Which Industry Leaders Are Driving Innovation Across The Liraglutide And Semaglutide Market?

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

How Do Regional Market Performances Compare Within The Liraglutide And Semaglutide Industry?

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Liraglutide And Semaglutide Market Report:

https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

Browse Through More Reports Similar to the Global Liraglutide And Semaglutide Market 2025, By The Business Research Company

Gluten Free Food Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gluten-free-food-global-market-report

Glutamic Acid Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report

Self Monitoring Blood Glucose Smbg Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/self-monitoring-blood-glucose-smbg-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795